PR Newswire (US) — Health·HK·Wed, 02 Sep 2026 21:00:00 UTC

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

HONG KONG, Sept. 2, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Data Monitoring Committee (IDMC), met the key...

Open original ↗Open in cockpit

Read releases like this the second they cross the wire.

1,200+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 7-day free trial, no card required.

Start the free trial →

Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.

PPN Source →

Shared via PPN World — real-time press release intelligence.